2022-10-19 08:00 Regulatory
Biovica today announces that the company has submitted its CLIA lab application, marking yet another significant milestone for the US commercial launch of the recent FDA cleared test DiviTum®TKa. Biovica is now prepared to receive, analyze, and report...
2022-10-18 08:45 Regulatory
The shareholders of Biovica International AB, reg. no. 556774-6150, (the "Company") are hereby invited to the extra general meeting to be held on Monday 7 November 2022, at 13.00 CET at Baker & McKenzie Advokatbyrå's premises...
2022-10-18 08:42 Regulatory
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEELAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, OR ANY OTHER JURISDICTION...
2022-08-31 16:10 Regulatory
The annual general meeting of Biovica International AB ("Biovica" or the "Company") was held today on 31 August 2022 and the following resolutions were passed by the meeting. ADOPTION OF THE INCOME STATEMENT AND BALANCE SHEET The annual...
2022-08-31 08:00 Regulatory Interim
Significant events during the first quarter · Results with DiviTum®TKa at ASCO · DiviTum®TKa highlighted at ASCO in an oral presentation · Biovica’s CFO will terminate employment in December 2022 ·...
2022-08-15 15:00 Regulatory
Biovica, active in cancer diagnostics, is hosting a market update due DiviTum®TKa’s US market approval received on July 29 from the US Food and Drug Administration (FDA). At the update on Thursday 18 August 15.00-16.00 CET, CEO Anders Rylander...
2022-07-30 13:00 Regulatory
Biovica, active in cancer diagnostics, today announces that FDA has granted 510(k) clearance for the product DiviTum®TKa as an aid in monitoring disease progression in previously diagnosed hormone receptor positive, metastatic postmenopausal female...
2022-07-27 08:00 Regulatory
The shareholders of Biovica International AB, reg. no. 556774-6150, (the "Company") are hereby invited to the annual general meeting on Wednesday 31 August 2022. The board of directors has decided that the annual general meeting shall only be...
2022-06-30 17:45 Regulatory
Biovica, active in cancer diagnostics, today announces that the company’s CFO and deputy CEO Cecilia Driving today has submitted her letter of resignation. A process to recruit a replacement is immediately initiated. Cecilia Driving, who has been...
2022-06-30 08:00 Regulatory Annual
Annual report for the financial year 2021/2022 for Biovica International AB is published today on our website. Financials – Biovica Contact Anders Rylander, CEO Phone: +46-18-444 48 35 E-mail: anders.rylander@biovica.com Cecilia Driving, EVP CFO...

>4,500

Numbers of patients in studies

28

Publications

22

Pharma Projects

Are you a US resident?

Only US residents will be able to qualify for this program

No